

## **DATA SHEET**

## For research use only. Not for use in humans.

Reagent:	Human Immunodeficiency Virus Type 1 p51 Reverse Transcriptase Protein, Recombinant from Escherichia coli
Catalog Number:	ARP-2896
Lot Number:	190117
Release Category:	C
Provided:	Each vial contains approximately 25 micrograms of ARP-2896 in 50 mM Tris-HCl, pH 7.0, 25 mM NaCl, 1 mM EDTA and 50% (v/v) glycerol at a concentration of 1 mg per mL. Purity was > 85% as determined by Coomassie Blue Staining.
Description:	ARP-2896 is a full-length, human immunodeficiency virus type 1 (HIV-1) p51 reverse transcriptase (RT) subunit recombinant protein derived from a patient sample.
Special Characteristics:	ARP-2896 is produced in an <i>Escherichia coli</i> expression system and purified by immobilized affinity chromatography (IMAC) and cation exchange chromatography. This protein contains an N-terminal hexa-histidine tag and is non-glycosylated. The molecular weight of ARP-2896 is approximately 53 kilodaltons. The integrity of the protein is determined immunologically with anti-RT antibodies. It is weakly active as a DNA polymerase if salt is reduced from standard RT assay buffer. This protein can also be used for antibody production.
Recommended Storage:	ARP-2896 should be stored at -80°C or colder immediately upon arrival. Avoid freeze-thaw cycles as reagent degradation may result.
Contributor:	Dr. Stuart Le Grice
References:	Howard, K. J., et al. "Reconstitution and Properties of Homologous and Chimeric HIV-1.HIV-2 p66.p51 Reverse Transcriptase." <u>J. Biol. Chem.</u> 266 (1991): 23003-23009. PubMed: <u>1720776</u> .
	Jacques, P. S., et al. "Modulation of HIV-1 Reverse Transcriptase Function in "Selectively Deleted" p66/p51 Heterodimers." <u>J. Biol. Chem.</u> 269 (1994): 1388-1393. PubMed: <u>7507107</u> .
	Le Grice, S. F., C. E. Cameron and S. J. Benkovic. "Purification and Characterization of Human Immunodeficiency Virus Type 1 Reverse Transcriptase." <u>Methods Enzymol.</u> 262 (1995): 130-144. PubMed: <u>8594344</u> .
	Le Grice, S. F., et al. "Subunit-Selective Mutagenesis Indicates Minimal Polymerase Activity in Heterodimer-Associated p51 HIV-1 Reverse Transcriptase." <u>EMBO J.</u> 10 (1991): 3905-3911. PubMed: <u>1718745</u> .
	Lederer, H., et al. "Domain Structure of the Human Immunodeficiency Virus Reverse Transcriptase." <u>EMBO J.</u> 11 (1992): 1131-1139. PubMed: <u>1372248</u> .
	Schatz, O., J. Mous and S. F. Le Grice. "HIV-1 RT-Associated Ribonuclease H Displays Both Endonuclease and 3'5' Exonuclease Activity." <u>EMBO J.</u> 9 (1990): 1171-1176. PubMed: <u>1691093</u> .
Citation:	Acknowledgment for publications should read "The following reagent was obtained through the NIH HIV Reagent Program, Division of AIDS, NIAID, NIH: Human Immunodeficiency Virus Type 1 p51 Reverse Transcriptase Protein, Recombinant from <i>Escherichia coli</i> , ARP-2896, contributed by Dr. Stuart Le Grice." Also include the references cited in any publications.

NIH HIV Reagent Program www.hivreagentprogram.org



Biosafety Level: 1	Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. <u>Biosafety in Microbiological and Biomedical Laboratories</u> . 6th ed. Washington, DC: U.S. Government Printing Office, 2020; see <u>www.cdc.gov/biosafety/publications/bmbl5/index.htm</u> .
Disclaimers:	You are authorized to use this product for research use only. It is not intended for use in humans.
	Use of this product is subject to the terms and conditions of the NIH HIV Reagent Program Material Transfer Agreement (MTA). The MTA is available on our Web site at <u>www.hivreagentprogram.org</u> .
	While the NIH HIV Reagent Program uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC <sup>®</sup> nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC <sup>®</sup> nor the U.S. Government warrants that such information has been confirmed to be accurate.
	This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC <sup>®</sup> and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC <sup>®</sup> , their suppliers and contributors to the NIH HIV Reagent Program are not liable for damages arising from the misidentification or misrepresentation of products.
Use Restrictions:	<b>This material is distributed for internal research purposes only.</b> This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.
Note:	ARP-2896 is limited to two aliquots per lab per year. Larger amounts can be obtained upon request from the contributor.
	Scientists at for-profit institutions or who intend commercial use of this reagent must contact the Director of Contracts and Tangible Assets, Email: <u>stacy.fening@case.edu</u> , and specify the name of the reagent and a description of the intended use, before the reagent can be released.
	ATCC <sup>®</sup> is a trademark of the American Type Culture Collection.